DNA sequencing company Illumina Inc (NASDAQ:ILMN) said on Monday that it plans to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology under a non-exclusive collaboration agreement with Roche, a pharmaceuticals company.
NGS has the potential to transform cancer risk prediction, detection, diagnosis, treatment and monitoring. This agreement brings together complementary capabilities of each company to broaden global adoption of NGS in cancer care.
Under the terms of the 15 year agreement, Illumina will grant Roche with rights to develop and distribute in-vitro diagnostic (IVD) tests on Illumina's NextSeq 550Dx System, as well as on its future portfolio of diagnostic (Dx) sequencing systems, including NovaSeqDx.
In conjunction with the agreement, Roche will collaborate with Illumina to complement Illumina's comprehensive pan-cancer assay, TruSight Oncology 500 (TSO 500), with new companion diagnostic (CDx) claims.
The financial terms of the deal were not disclosed by the companies.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886